PE-162 Poly(lactic-co-glycolic acid) Nanospheres Containing Protease Inhibitors, Camostat Mesilate and Nafamostat Mesilate : Therapeutic Potential for Treating Atherosclerosis(Cardiovascular pharmacology, basic/clinical(03)(H),Poster Session(English),The

スポンサーリンク

概要

• 論文の詳細を見る
• 社団法人日本循環器学会の論文
• 2008-03-01

著者

• Fujii Satoshi

  Nagoya City University Graduate School of Pharmaceutical Sciences

• Hazemoto Norio

  Nagoya City University

• Noda Yasuhiro

  Nagoya City University

• Fujii Satoshi

  Nagoya City University

• Fujii Satoshi

  Nagoya City Univ. Nagoya Jpn

関連論文

• OJ-152 Do JCD, IDF and NCEP Criteria of Metabolic Syndrome Predict Cardiovascular Events? : 3-Year Cohort Study of 3,343 Japanese Men(Preventive medicine / Epidemiology / Education(02)(H),Oral Presentation (Japanese),The 72nd Annual Scientific Meeting of
• PE-581 Insulin Regulates Plasminogen Activator Inhibitor 1 Expression in Hepatocytes and in Mice Liver Through Statin-Sensitive Pathway(Thromboembolism/Antithrombotic therapy/Thrombolysis(03)(H),Poster Session(English),The 72nd Annual Scientific Meeting o
• PE-162 Poly(lactic-co-glycolic acid) Nanospheres Containing Protease Inhibitors, Camostat Mesilate and Nafamostat Mesilate : Therapeutic Potential for Treating Atherosclerosis(Cardiovascular pharmacology, basic/clinical(03)(H),Poster Session(English),The

スポンサーリンク